ENTA
Price
$7.54
Change
+$0.31 (+4.29%)
Updated
Jul 18 closing price
Capitalization
161.18M
21 days until earnings call
SCPH
Price
$4.94
Change
+$0.08 (+1.65%)
Updated
Jul 18 closing price
Capitalization
260.79M
16 days until earnings call
Interact to see
Advertisement

ENTA vs SCPH

Header iconENTA vs SCPH Comparison
Open Charts ENTA vs SCPHBanner chart's image
Enanta Pharmaceuticals
Price$7.54
Change+$0.31 (+4.29%)
Volume$213.59K
Capitalization161.18M
scPharmaceuticals
Price$4.94
Change+$0.08 (+1.65%)
Volume$402.67K
Capitalization260.79M
ENTA vs SCPH Comparison Chart in %
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. SCPH commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and SCPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (ENTA: $7.54 vs. SCPH: $4.94)
Brand notoriety: ENTA and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 134% vs. SCPH: 110%
Market capitalization -- ENTA: $161.18M vs. SCPH: $260.79M
ENTA [@Biotechnology] is valued at $161.18M. SCPH’s [@Biotechnology] market capitalization is $260.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 4 TA indicator(s) are bullish while SCPH’s TA Score has 5 bullish TA indicator(s).

  • ENTA’s TA Score: 4 bullish, 5 bearish.
  • SCPH’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SCPH is a better buy in the short-term than ENTA.

Price Growth

ENTA (@Biotechnology) experienced а +14.94% price change this week, while SCPH (@Biotechnology) price change was +12.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

ENTA is expected to report earnings on Aug 11, 2025.

SCPH is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SCPH($261M) has a higher market cap than ENTA($161M). SCPH YTD gains are higher at: 39.548 vs. ENTA (31.130). SCPH (-83.9M) and ENTA (-87.12M) have comparable annual earnings (EBITDA) . ENTA has more cash in the bank: 193M vs. SCPH (57.5M). SCPH has less debt than ENTA: SCPH (52.4M) vs ENTA (58.7M). ENTA has higher revenues than SCPH: ENTA (64.5M) vs SCPH (42M).
ENTASCPHENTA / SCPH
Capitalization161M261M62%
EBITDA-87.12M-83.9M104%
Gain YTD31.13039.54879%
P/E RatioN/AN/A-
Revenue64.5M42M154%
Total Cash193M57.5M336%
Total Debt58.7M52.4M112%
FUNDAMENTALS RATINGS
ENTA vs SCPH: Fundamental Ratings
ENTA
SCPH
OUTLOOK RATING
1..100
7217
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4437
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (65) in the Pharmaceuticals Major industry is in the same range as ENTA (95) in the Biotechnology industry. This means that SCPH’s stock grew similarly to ENTA’s over the last 12 months.

SCPH's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ENTA (100) in the Biotechnology industry. This means that SCPH’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (98) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that ENTA’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as ENTA (44) in the Biotechnology industry. This means that SCPH’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for SCPH (100) in the Pharmaceuticals Major industry. This means that ENTA’s stock grew significantly faster than SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTASCPH
RSI
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
61%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 14 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
61%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TNYZF0.680.02
+3.50%
Tiny Ltd.
ANLDF0.09N/A
+2.04%
Anfield Energy Inc.
HRBK19.800.35
+1.80%
Harbor Bankshares Corporation
HRSEF116.47N/A
N/A
Hirose Electric
XPNGF8.15N/A
N/A
XPeng Inc.

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+4.29%
ALEC - ENTA
40%
Loosely correlated
-4.79%
BEAM - ENTA
40%
Loosely correlated
+1.47%
SCPH - ENTA
38%
Loosely correlated
+1.65%
ADCT - ENTA
37%
Loosely correlated
-0.33%
KRYS - ENTA
37%
Loosely correlated
-1.77%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with AURA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
+1.65%
AURA - SCPH
46%
Loosely correlated
-5.76%
AUTL - SCPH
46%
Loosely correlated
-0.41%
BEAM - SCPH
45%
Loosely correlated
+1.47%
YMAB - SCPH
44%
Loosely correlated
-0.23%
CRSP - SCPH
44%
Loosely correlated
+18.22%
More